The FDA cleared a 510(k) on May 6, 2013 for enhancements to the RMS Subcutaneous Safety Needle Sets which included formally recognizing our clinical studies to support the Safety Needle claim, additional lengths of 4mm and 14mm, use for greater than 24 hours, non-pyrogenic claims, the use of up to eight sites and the 24 gauge needle.

The Director loan with a balance of $437,832 as of February 28, 2013 was fully paid on May 17, 2013 as we concluded that the cash on hand was not earning the cost of the interest.